Phase 4
Completed N=108
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
Source: ClinicalTrials.gov NCT00361283 ↗Enrolled (actual)
108
Serious AEs
0.0%
Results posted
May 2012
Primary outcomePrimary: Mean Change in Level: Week 16-baseline in Ena-78 — -111.2 pg/ml — p=0.15
Summary
The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Level: Week 16-baseline in Ena-78 |
-111.2 | 0.15 |
Eligibility Criteria
Inclusion Criteria
- 18+ years old
- Normocholesterolemic
Exclusion Criteria
- Cardiovascular disease or risk equivalents
- Malignancy
- Active alcohol abuse
- Contraindications to statins
- Interacting drugs
- Chronic anti-inflammatory drugs
Data sourced from ClinicalTrials.gov (NCT00361283). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.